News
UK bladder cancer patients get early access to Bavencio
Merck and Pfizer’s Bavencio (avelumab) is now available under the UK’s Early Access to Medicines Scheme (EAMS) giving some patients with bladder cancer the chance to receive treatment with the immunotherapy before its approval in Europe.